Eli Lilly (LLY)

Eli Lilly is growing quickly, lowering realized prices, and building its next wave of drugs. Here's what the numbers say about margins, valuation, and the catalysts that matter next.

Is this company the biggest dark horse in the chronic weight management space?

AI-driven "biointelligence" is reshaping healthcare investing, with Guardant Health, Illumina, Eli Lilly and Moderna emerging as key stocks as data-driven testing, sequencing and therapies compound.

Polls suggest a divided government after the midterms, a scenario that historically benefits healthcare stocks. Here's how the XLV and IHF ETFs compare for investors eyeing the sector.

Buffett has warned about "gambling" in the market.

Viking Therapeutics raised $575 million to fund major obesity drug trials, develop its pipeline, and support commercial development of any approvals for VK2735.

Novo is facing some headwinds, but it has a plan to overcome them.

It was Griffin's biggest add for Citadel last quarter.

The gene-editing biotech stock is down more than 12% this year.

These funds can help you weather any storm that might be on the way.

Eli Lilly's greatest strength isn't Zepbound. It is the company's drug discovery engine.

A new government-funded study found that GLP-1 drugs slow the aging process in mice.

The Lilly Foundation is unloading 300,000 shares of the stock.

The stock has soared 25% in six months.

International stock ETFs offer superior diversification, lower valuations, and higher yields than S&P 500 ETFs like VOO.

Even if you add nothing at all, $1,000 can accomplish a lot over decades.

Different categories offer different benefits for investors.

On Oct. 14, 2026, a hotter-than-expected CPI report pressures growth stocks and the semiconductor selloff continues.

It's banking on winners continuing to run.

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...

Kura Oncology (NASDAQ:KURA) and its newly formed affiliate Caspian Therapeutics outlined plans to develop KO-7246, an oral menin inhibitor, for diabetes, citing preclinical data that the companies said showed beta-cell expansion, improved glucose control and sustained effects after treatment ended.